Pfizer To Pay $2.3B In Bextra Off-Label Marketing Suit

By Jesse Greenspan

Law360, New York (January 27, 2009, 12:00 AM ET) -- Pfizer Inc. has agreed to pay $2.3 billion to settle allegations that it improperly marketed the now-defunct anti-inflammatory drug Bextra, the pharmaceutical giant disclosed Monday.

The settlement, which still needs court approval, was reached with the office of U.S. Attorney Michael Sullivan of the District of Massachusetts.

According to a statement put out by Pfizer, the deal will resolve “previously disclosed investigations regarding allegations of past off-label promotional practices concerning Bextra, as well as other open investigations.”

The company added that its net income for the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles